Skip to main content
Top
Published in: Irish Journal of Medical Science (1971 -) 2/2017

01-05-2017 | Original Article

Factors associated with the incidence of serious adverse events in patients admitted with COPD acute exacerbation

Authors: M.-T. García-Sanz, J.-C. Cánive-Gómez, N. García-Couceiro, L. Senín-Rial, S. Alonso-Acuña, A. Barreiro-García, E. López-Val, L. Valdés, F.-J. González-Barcala

Published in: Irish Journal of Medical Science (1971 -) | Issue 2/2017

Login to get access

Abstract

Background

Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a common cause of hospitalization. Patient outcome and prognosis following AECOPD are variable. The aim of this study is to identify the factors associated with the incidence of serious adverse events (SAE), defined as need for ICU admission, noninvasive ventilation, death during hospitalization or early readmission, in those patients admitted with AECOPD.

Methods

We conducted a retrospective study by reviewing the medical records of all patients admitted with AECOPD in the University Hospital Complex of Santiago de Compostela in 2007 and 2008. To identify variables independently associated with SAE incidence, we conducted a logistic regression including those variables which proved to be significant in the univariate analysis.

Results

757 patients were assessed (mean age 74.8 years, SD 11.26), 77.2 % male, and 186 (24.6 %) of the patients assessed experienced an SAE. Factors associated with SAE in multivariate analysis were anticholinergic therapy (OR 3.19; CI 95 %: 1.16; 8.82), oxygen therapy at home (OR 3.72; CI 95 %: 1.62; 8.57), oxygen saturation at admission (OR 0.93; CI 95 %: 0.88; 0.99) and serum albumin (OR 0.26; CI 95 %: 0.1; 0.66).

Conclusion

Oxygen therapy at home, anticholinergic therapy as baseline treatment, lower oxygen saturation at admission and lower serum albumin level seem to be associated with higher incidence of SAE in patients with AECOPD.
Literature
1.
go back to reference Celli BR, MacNee W (2004) ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23:932–946CrossRefPubMed Celli BR, MacNee W (2004) ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23:932–946CrossRefPubMed
2.
go back to reference Ornek T, Tor M, Altýn R, Atalay F, Geredeli E, Soylu O et al (2012) Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Int Med Sci 9:285–290CrossRef Ornek T, Tor M, Altýn R, Atalay F, Geredeli E, Soylu O et al (2012) Clinical factors affecting the direct cost of patients hospitalized with acute exacerbation of chronic obstructive pulmonary disease. Int Med Sci 9:285–290CrossRef
3.
go back to reference Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa JF et al (2004) IMPAC study group: Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59:387–395CrossRefPubMedPubMedCentral Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa JF et al (2004) IMPAC study group: Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 59:387–395CrossRefPubMedPubMedCentral
4.
go back to reference Donaldson GC, Seemungal TAR, Bhowmik A (2002) JA W. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57:847–852CrossRefPubMedPubMedCentral Donaldson GC, Seemungal TAR, Bhowmik A (2002) JA W. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57:847–852CrossRefPubMedPubMedCentral
5.
go back to reference Tsimogianni AM, Papiris SA, Stathopoulos GT, Manali ED, Roussos C (2009) A K. Predictors of outcome after exacerbation of chronic obstructive pulmonary disease. J Gen Intern Med 24:1043–1048CrossRefPubMedPubMedCentral Tsimogianni AM, Papiris SA, Stathopoulos GT, Manali ED, Roussos C (2009) A K. Predictors of outcome after exacerbation of chronic obstructive pulmonary disease. J Gen Intern Med 24:1043–1048CrossRefPubMedPubMedCentral
6.
go back to reference Stiell IG, Clement CM, Aaron SD, Rowe BH, Perry JJ, Brison RJ et al (2014) Clinical characteristics associated with adverse events in patients with exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. CMAJ. doi:10.1503/cmaj.130968 PubMedPubMedCentral Stiell IG, Clement CM, Aaron SD, Rowe BH, Perry JJ, Brison RJ et al (2014) Clinical characteristics associated with adverse events in patients with exacerbation of chronic obstructive pulmonary disease: a prospective cohort study. CMAJ. doi:10.​1503/​cmaj.​130968 PubMedPubMedCentral
8.
go back to reference Matkovic Z, Huerta A, Soler N, Domingo R, Gabarrús A, Torres A et al (2012) Predictors of adverse outcome in patients hospitalised for exacerbation of chronic obstructive pulmonary disease. Respiration 84:17–26CrossRefPubMed Matkovic Z, Huerta A, Soler N, Domingo R, Gabarrús A, Torres A et al (2012) Predictors of adverse outcome in patients hospitalised for exacerbation of chronic obstructive pulmonary disease. Respiration 84:17–26CrossRefPubMed
9.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie C (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie C (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed
10.
go back to reference Barba R, Zapatero A, Losa JE, Marco J, Plaza S, Rosado C et al (2012) The impact of weekends on outcome for acute exacerbations of COPD. Eur Respir J 39:46–50CrossRefPubMed Barba R, Zapatero A, Losa JE, Marco J, Plaza S, Rosado C et al (2012) The impact of weekends on outcome for acute exacerbations of COPD. Eur Respir J 39:46–50CrossRefPubMed
11.
go back to reference Quintana JM, Unzurrunzaga A, Garcia-Gutierrez S, Gonzalez N, Lafuente I, Bare M et al (2015) IRYSS-COPD Group. Predictors of Hospital Length of Stay in Patients with Exacerbations of COPD: A Cohort Study. J Gen Intern Med 30:824–831CrossRefPubMed Quintana JM, Unzurrunzaga A, Garcia-Gutierrez S, Gonzalez N, Lafuente I, Bare M et al (2015) IRYSS-COPD Group. Predictors of Hospital Length of Stay in Patients with Exacerbations of COPD: A Cohort Study. J Gen Intern Med 30:824–831CrossRefPubMed
12.
go back to reference Ashton CM, Kuykendall DH, Johnson ML et al (1995) The association between the quality of inpatient care and early readmission. Ann Intern Med 122(6):412–415CrossRef Ashton CM, Kuykendall DH, Johnson ML et al (1995) The association between the quality of inpatient care and early readmission. Ann Intern Med 122(6):412–415CrossRef
13.
go back to reference Lee Chang-Hoon, Choi Seongmi, EunJinJang Han-Mo Yang, Yoon Ho Il, Kim Yun Jung et al (2015) Inhaled bronchodilators and the risk of tachyarrhythmias. Int J Cardiol 190:133–139CrossRefPubMed Lee Chang-Hoon, Choi Seongmi, EunJinJang Han-Mo Yang, Yoon Ho Il, Kim Yun Jung et al (2015) Inhaled bronchodilators and the risk of tachyarrhythmias. Int J Cardiol 190:133–139CrossRefPubMed
14.
go back to reference Horita Nobuyuki, Miyazawa Naoki, Morita Satoshi, Kojima Ryota, Kimura Naoko, Kaneko T et al (2013) Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study. Respir Res 14:62CrossRefPubMedPubMedCentral Horita Nobuyuki, Miyazawa Naoki, Morita Satoshi, Kojima Ryota, Kimura Naoko, Kaneko T et al (2013) Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study. Respir Res 14:62CrossRefPubMedPubMedCentral
15.
16.
go back to reference Curkendall SM, DeLuise C, Jones JK et al (2006) Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan, Canada. Ann Epidemiol 16:63–70CrossRefPubMed Curkendall SM, DeLuise C, Jones JK et al (2006) Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan, Canada. Ann Epidemiol 16:63–70CrossRefPubMed
17.
go back to reference vanVlymen JM, Parlow J (1997) The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period. Anesth Analg 84:148–154CrossRef vanVlymen JM, Parlow J (1997) The effects of reversal of neuromuscular blockade on autonomic control in the perioperative period. Anesth Analg 84:148–154CrossRef
18.
go back to reference Mathew J, Hunsberger S, Fleg J et al (2000) Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 118:914–922CrossRefPubMed Mathew J, Hunsberger S, Fleg J et al (2000) Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 118:914–922CrossRefPubMed
19.
go back to reference Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R et al (2013) Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 173:1175–1185CrossRefPubMed Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R et al (2013) Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 173:1175–1185CrossRefPubMed
20.
go back to reference Singh S, Loke YK, Enright PL, CD F (2011) Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 342:d3215. doi:10.1136/bmj.d3215 Singh S, Loke YK, Enright PL, CD F (2011) Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ 342:d3215. doi:10.​1136/​bmj.​d3215
21.
go back to reference Cheyne L, Irvin-Sellers MJ, White J (2015) Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 9: CD009552 Cheyne L, Irvin-Sellers MJ, White J (2015) Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 9: CD009552
22.
go back to reference Dong YH, Lin HH, Shau WY, Wu YC, Chang CH (2013) MS L. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 68:48–56CrossRefPubMed Dong YH, Lin HH, Shau WY, Wu YC, Chang CH (2013) MS L. Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials. Thorax 68:48–56CrossRefPubMed
23.
go back to reference Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG (2013) MC S. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J 42:606–615CrossRefPubMed Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG (2013) MC S. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J 42:606–615CrossRefPubMed
24.
go back to reference Gershon A, Croxford R, To T, Stanbrook MB, Upshur R, Sanchez-Romeu P et al (2011) Comparison of inhaled long-acting β-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study. Ann Intern Med 154:583–592CrossRefPubMed Gershon A, Croxford R, To T, Stanbrook MB, Upshur R, Sanchez-Romeu P et al (2011) Comparison of inhaled long-acting β-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study. Ann Intern Med 154:583–592CrossRefPubMed
25.
go back to reference Palop-Cervera M, De Diego-Damiá A, León-Fábregas M, Bravo-Gutiérrez FJ (2010) Factores predictores de mortalidad en pacientes con enfermedad pulmonar obstructiva crónica y exacerbaciones frecuentes. Rev Clin Esp 210:323–331CrossRef Palop-Cervera M, De Diego-Damiá A, León-Fábregas M, Bravo-Gutiérrez FJ (2010) Factores predictores de mortalidad en pacientes con enfermedad pulmonar obstructiva crónica y exacerbaciones frecuentes. Rev Clin Esp 210:323–331CrossRef
26.
go back to reference Bahadori K, FitzGerald JM, Levy RD, Fera T (2009) Risk factors and outcomes associated with chronic obstructive pulmonary disease exacerbations requiring hospitalization. Can Respir J 16:e43–e49CrossRefPubMedPubMedCentral Bahadori K, FitzGerald JM, Levy RD, Fera T (2009) Risk factors and outcomes associated with chronic obstructive pulmonary disease exacerbations requiring hospitalization. Can Respir J 16:e43–e49CrossRefPubMedPubMedCentral
27.
go back to reference García-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM (2003) Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 58:100–105CrossRefPubMedPubMedCentral García-Aymerich J, Farrero E, Felez MA, Izquierdo J, Marrades RM (2003) Risk factors of readmission to hospital for a COPD exacerbation: a prospective study. Thorax 58:100–105CrossRefPubMedPubMedCentral
28.
go back to reference Molinos L, Clemente LG, Miranda B, Alvarez C, Del Busto B, Cocina BR et al (2009) Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 58:417–424CrossRefPubMed Molinos L, Clemente LG, Miranda B, Alvarez C, Del Busto B, Cocina BR et al (2009) Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect 58:417–424CrossRefPubMed
29.
go back to reference Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulvas G, Pehlivan E et al (2005) Factors affecting survival of hospitalised patients with COPD. Eur Respir J 26:234–241CrossRefPubMed Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulvas G, Pehlivan E et al (2005) Factors affecting survival of hospitalised patients with COPD. Eur Respir J 26:234–241CrossRefPubMed
30.
go back to reference Girón R, Matesanz C, García-Río F, deSantiago E, Mancha A, Rodríguez-Salvanés F et al (2009) Nutritional state during COPD exacerbation: clinical and prognostic implications. Ann Nutr Metab 54:52–58CrossRefPubMed Girón R, Matesanz C, García-Río F, deSantiago E, Mancha A, Rodríguez-Salvanés F et al (2009) Nutritional state during COPD exacerbation: clinical and prognostic implications. Ann Nutr Metab 54:52–58CrossRefPubMed
31.
go back to reference Chen CW, Chen YY, Lu CL, Chen SC, Chen YJ, Lin MS et al (2015) Severe hypoalbuminemia is a strong independent risk factor for acute respiratory failure in COPD: a nationwide cohort study. Int J Chron Obstruct Pulmon Dis 10:1147–1154CrossRefPubMedPubMedCentral Chen CW, Chen YY, Lu CL, Chen SC, Chen YJ, Lin MS et al (2015) Severe hypoalbuminemia is a strong independent risk factor for acute respiratory failure in COPD: a nationwide cohort study. Int J Chron Obstruct Pulmon Dis 10:1147–1154CrossRefPubMedPubMedCentral
32.
go back to reference Ai-Ping C, Lee KH, Lim T (2005) In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest 128:518–524CrossRefPubMed Ai-Ping C, Lee KH, Lim T (2005) In-hospital and 5-year mortality of patients treated in the ICU for acute exacerbation of COPD: a retrospective study. Chest 128:518–524CrossRefPubMed
33.
go back to reference Sin DD, Anthonisen NR, Soriano JB, Agusti A (2006) Mortality in COPD: Role of comorbidities. Eur Respir J 28:1245–1257CrossRefPubMed Sin DD, Anthonisen NR, Soriano JB, Agusti A (2006) Mortality in COPD: Role of comorbidities. Eur Respir J 28:1245–1257CrossRefPubMed
34.
35.
go back to reference Almagro P, Cabrera FJ, Diez J, Boixeda R, Alonso-Ortiz MB, Murio C et al (2012) Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD. Chest 142:1126–1133CrossRefPubMed Almagro P, Cabrera FJ, Diez J, Boixeda R, Alonso-Ortiz MB, Murio C et al (2012) Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD. Chest 142:1126–1133CrossRefPubMed
36.
go back to reference Carrasco-Sánchez FJ, Recio-Iglesias J, Amorós JG (2014) Complementary treatment of acute heart failure in patients with diabetes, chronic obstructive pulmonary disease or anemia. Med Clin (Barc) 142(Suppl 1):59–65. doi:10.1016/S0025-7753(14)70085-5 CrossRef Carrasco-Sánchez FJ, Recio-Iglesias J, Amorós JG (2014) Complementary treatment of acute heart failure in patients with diabetes, chronic obstructive pulmonary disease or anemia. Med Clin (Barc) 142(Suppl 1):59–65. doi:10.​1016/​S0025-7753(14)70085-5 CrossRef
37.
go back to reference Parappil A, Depczynski B, Collett P, Marks G (2010) Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 15:918–922CrossRefPubMed Parappil A, Depczynski B, Collett P, Marks G (2010) Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 15:918–922CrossRefPubMed
38.
go back to reference Abroug F, Ouanes-Besbes L, Fkih-Hassen M, Ouanes I, Ayed S, Dachraoui F et al (2014) Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation. Eur Respir J 43:717–724CrossRefPubMed Abroug F, Ouanes-Besbes L, Fkih-Hassen M, Ouanes I, Ayed S, Dachraoui F et al (2014) Prednisone in COPD exacerbation requiring ventilatory support: an open-label randomised evaluation. Eur Respir J 43:717–724CrossRefPubMed
39.
go back to reference Chakrabarti B, Angus RM, Agarwal S, Lane S, Calverley P (2009) Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax 64:857–862CrossRefPubMed Chakrabarti B, Angus RM, Agarwal S, Lane S, Calverley P (2009) Hyperglycaemia as a predictor of outcome during non-invasive ventilation in decompensated COPD. Thorax 64:857–862CrossRefPubMed
40.
go back to reference Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM et al (2006) Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 61:284–289CrossRefPubMedPubMedCentral Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM et al (2006) Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 61:284–289CrossRefPubMedPubMedCentral
Metadata
Title
Factors associated with the incidence of serious adverse events in patients admitted with COPD acute exacerbation
Authors
M.-T. García-Sanz
J.-C. Cánive-Gómez
N. García-Couceiro
L. Senín-Rial
S. Alonso-Acuña
A. Barreiro-García
E. López-Val
L. Valdés
F.-J. González-Barcala
Publication date
01-05-2017
Publisher
Springer London
Published in
Irish Journal of Medical Science (1971 -) / Issue 2/2017
Print ISSN: 0021-1265
Electronic ISSN: 1863-4362
DOI
https://doi.org/10.1007/s11845-016-1431-9

Other articles of this Issue 2/2017

Irish Journal of Medical Science (1971 -) 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.